Insmed Inc

insmed.com

Insmed Inc (NASDAQ: INSM) is a biopharmaceutical company that develops and commercializes therapies for serious and rare diseases. Revenue is generated through product sales of approved pharmaceutical treatments to patients and healthcare providers. The filing excerpts provided do not contain sufficient detail to characterize Insmed's competitive position, specific products, geographic footprint, segment revenue breakdown, or other operational specifics within the required evidentiary standard.

Peers: ACADIA Pharmaceuticals Inc AMICUS THERAPEUTICS, INC. Arrowhead Pharmaceuticals Inc BioCryst Pharmaceuticals Inc Denali Therapeutics Inc Relay Therapeutics Inc Sage Therapeutics, Inc. Ultragenyx Pharmaceutical Inc Vir Biotechnology Inc

Source: SEC 10-K, filed 2026-02-19

Dive deeper

Financial Snapshot

Revenue

TTM

$819.6M

Gross Margin

TTM

80.24%

Net Income

TTM

-$1.184B

Current Assets

2026 Q1

$1.613B

Current Liabilities

2026 Q1

$361.0M

Current Ratio

2026 Q1

446.85%

Total Assets

2026 Q1

$2.076B

Total Liabilities

2026 Q1

$1.371B

Book Value

2026 Q1

$704.9M

Cash

2026 Q1

$582.2M

P/E

Last 4 Quarters

N/A

Free Cash Flow

TTM

-$921.6M

Stock Price

Market Cap: $25.059 Billion